Identifying the Role of Inflammatory Cytokines in Symptom Production in Multiple Myeloma

Inclusion Criteria:

1. Must speak and understand English;

2. Must be diagnosed with MM and meet one of the following criteria: 1) have been
treated for MM with steroids only, or have received no more than two cycles of
induction chemotherapy for MM and are going to be treated with bortezomib or
thalidomide for induction therapy; 2) have received induction therapy and have been
approved (or are being approved) medically and financially to receive autologous
hematopoietic stem cell transplantation (Auto-HSCT); 3) cross sectional study
patients will be either with a current diagnosis of asymptomatic MM not receiving
treatment; or at least 12 months from the MM diagnosis, had received induction
therapy, with or without received autologous hematopoietic stem cell transplantation
(Auto-HSCT) and follow-up treatments. This cohort for a cross sectional survey may
include the cases been enrolled, either completed or dropped from the same study. It
may also include patients who did not participate on the first phase of the protocol
(longitudinal cohort).

3. Patients >= 18 years old.

Exclusion Criteria:

1. Patients who do not understand the intent of the study, so cannot or will not give
informed consent

2. Patients who are unable to use the Interactive Voice Response (IVR) system due to
physical limitations (e.g., hearing impairment).

3. Induction therapy patients with a neuropathy score of 3 or greater on the NCI's
Common Terminology Criteria (CTC version 3.0) either at the beginning of induction
chemotherapy or after 1-2 cycles of chemotherapy as a result of previous treatment or
from some other comorbid cause. This exclusion criteria does apply to the auto-HSCT
patients.